Cronos Group (TSE:CRON) Announces Quarterly Earnings Results

Cronos Group (TSE:CRONGet Free Report) announced its quarterly earnings data on Monday. The company reported C$0.06 earnings per share for the quarter, FiscalAI reports. Cronos Group had a negative return on equity of 0.87% and a negative net margin of 6.37%.The business had revenue of C$62.86 million during the quarter.

Cronos Group Price Performance

Shares of CRON stock traded up C$0.23 on Monday, reaching C$3.70. The company’s stock had a trading volume of 325,782 shares, compared to its average volume of 167,759. The company has a quick ratio of 24.01, a current ratio of 19.59 and a debt-to-equity ratio of 0.25. Cronos Group has a 12-month low of C$2.54 and a 12-month high of C$4.66. The company has a market capitalization of C$1.39 billion, a P/E ratio of -185.00, a PEG ratio of 0.12 and a beta of 1.12. The stock’s 50 day simple moving average is C$3.56 and its 200-day simple moving average is C$3.60.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Canaccord Genuity Group set a C$4.25 price objective on Cronos Group and gave the company a “buy” rating in a report on Tuesday, January 27th. TD Securities set a C$4.50 target price on Cronos Group and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, Cronos Group has an average rating of “Buy” and an average price target of C$4.38.

View Our Latest Stock Report on CRON

Cronos Group Company Profile

(Get Free Report)

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.

See Also

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.